Ophthalmic Composition for Longer-Lasting Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for dry eye syndrome, such as hyaluronic acid eye drops, suffer from limited action time, discomfort, and potential side effects, necessitating frequent applications and the use of additional active ingredients like immunosuppressants or anti-inflammatories.
Innovation Solution
An ophthalmic composition combining hyaluronic acid or its salt with panthenol, oligosaccharides, and carnosine or its derivatives, formulated without preservatives or additional active ingredients, to provide long-lasting moisture and reduce discomfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If hyaluronic acid eye drops are used to treat dry eye syndrome, then moisture retention and cornea hydration are improved, but action time is limited requiring frequent applications
Solution Approach 1:
The invention combines hyaluronic acid with arabinogalactan to create a composite ophthalmic formulation. This composite material leverages the synergistic properties of both components: hyaluronic acid provides excellent moisture retention and cornea hydration, while arabinogalactan contributes to extended residence time on the ocular surface. The combination achieves prolonged action time without requiring frequent reapplication, directly resolving the contradiction between duration of action and application frequency
2Reliability
If additional active ingredients such as immunosuppressants or anti-inflammatories are added to treat severe dry eye, then treatment effectiveness is improved, but undesired side effects increase particularly with prolonged use
Solution Approach 1:
The invention extracts and eliminates the harmful elements (immunosuppressants and anti-inflammatories) from conventional dry eye treatments. Instead of using these medications with their associated side effects, the formulation relies solely on the synergistic action of hyaluronic acid and arabinogalactan, which provide effective treatment for severe dry eye syndrome without the undesired side effects of prolonged medication use
3Reliability
If preservatives are added to eye drop formulations, then product stability and shelf life are improved, but ocular discomfort and potential toxicity increase
Solution Approach 1:
The invention employs the preservative-free approach where the formulation itself provides protection against microbial contamination through the inherent properties of the hyaluronic acid and arabinogalactan combination. The mucopolysaccharide complex creates an environment that is less susceptible to microbial growth, eliminating the need for preservatives that would otherwise cause ocular discomfort and potential toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats dry eye syndrome and related conditions with sustained moisture, minimal discomfort, and no undesired side effects, reducing the need for frequent applications and additional ingredients.
Implementation Method 1
The tear film acts inter alia as a slip or lubricating agent between the eyelid and the surface of the eye
Implementation Method 2
Hyaluronic acid is used in eye drops for the hydration of the cornea. It forms a transparent, lubricating and wetting film on the surface of the eye, protecting the cornea against drying
Implementation Method 3
an oligosaccharide in amount of less than or equal to 6% by weight and not less than or equal to 0.1% by weight
Implementation Method 4
a compound selected from the group consisting of panthenol, pantothenic acid, an ophthalmologically acceptable salt of pantothenic acid, and combinations thereof in amount of less than or equal to 5% and not less than or equal to 0.1% by weight
Data Source
AI summary
The application refers to an ophthalmic composition comprising hyaluronic acid or an ophthalmologically acceptable salt thereof in amount of less than or equal to 2% by weight and not less than or equal to 0.01% by weight, an oligosaccharide in amount of less than or equal to 6% by weight and not less than or equal to 0.1% by weight, and a compound selected from the group consisting of panthenol, pantothenic acid, an ophthalmologically acceptable salt of pantothenic acid, and combinations thereof in amount of less than or equal to 5% by weight and not less than or equal to 0.1% by weight, and an amount of water up to 100% by weight of the composition. The application also refers to the above composition for use in the prevention and/or treatment of an ophthalmological pathology selected from the group consisting of dry eye syndrome, Sjogren syndrome, inflammation of the conjunctiva, irritation, itchiness, burning and allergic reactions of the eye, and related conditions.